Drugs / Diltiazem
Diltiazem
also known as
Diltiazem Hydrochloride · 2% Diltiazem · Adizem · Adizem-60 · Adizem-sr · Adizem-xl · Altiazem · Angiozem 60 · +96 more
Small molecule targets CYP3A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | CARDIZEM LA | — | 2004-04-02 | fda.gov ↗ |
| Label expansion | US (FDA) | TIAZAC | — | 1998-01-30 | fda.gov ↗ |
| Label expansion | US (FDA) | DILACOR XR | — | 1995-03-02 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | CARDIZEM | — | 1986-07-28 – 1993-07-01 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | CARDIZEM CD | — | 1992-08-10 – 1992-10-15 | fda.gov ↗ |
| Approved | US (FDA) | CARDIZEM | — | 1982-11-05 | fda.gov ↗ |
Trials 67 · started per year
today
US approved 1982
1
1
1
1
1
2
5
3
1
2
4
2
3
7
2
2
2
1
1
2
5
6
1
2
4
3
2
19821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04790331 | Mar 2021 → Jan 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT03580590 | Sep 2018 → Nov 2019 | orthostatic hypotension 2 | Assiut University | Unknown | No outcome recorded |
| Phase 129 trials | ||||||
| Phase 1 | NCT07697625 | Jul → Sep 2026 overdue | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07232589 | Dec 2025 → May 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06818968 | Feb → Aug 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06554639 | Jul → Aug 2024 | prostate neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06662396 | Jun → Sep 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06692647 | Feb → Apr 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05745337 | Feb → Dec 2023 | atrial fibrillation, diastolic heart failure | University of Vermont | Unknown | No outcome recorded |
| Phase 1 | NCT05162222 | Dec 2021 → Jul 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04551963 | Nov 2020 → Feb 2022 | B-cell neoplasm | BeiGene | Completed | Mixed |
| Phase 1 | NCT02807909 | Jul → Aug 2016 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02526888 | Sep → Nov 2015 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02479204 | Apr 2015 → May 2016 | — | Viatris Innovation GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT02300259 | Nov 2014 → Apr 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02319148 | Jul → Oct 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02010970 | Dec 2013 → Feb 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02080780 | Sep → Oct 2013 | — | Ventrus Biosciences, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01852565 | May → Sep 2013 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01816529 | Mar → Jun 2013 | — | Ventrus Biosciences, Inc | Unknown | No outcome recorded |
| Phase 1 | NCT01821274 | Mar → Jul 2013 | irritant dermatitis | Ventrus Biosciences, Inc | Unknown | No outcome recorded |
| Phase 1 | NCT01816191 | Feb → Jul 2013 | ulcer of anus and rectum | Ventrus Biosciences, Inc | Unknown | No outcome recorded |
| Phase 1 | NCT01549496 | May → Sep 2012 | hepatitis C virus infection, hypertensive disorder | Ottawa Hospital Research Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT01261156 | Oct → Dec 2010 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01211808 | Sep → Oct 2010 | atrial fibrillation | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01124760 | May → Jul 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00733239 | Aug 2008 → Oct 2010 | opiate dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00645463 | Mar → Jun 2007 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00593463 | Sep 2006 → May 2010 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00039975 | ? → Apr 2004 | HIV infectious disease, hypertensive disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07456852 | Apr 2026 → Apr 2028 expected | digestive system cancer | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05563168 | Apr 2023 → Oct 2024 | COVID-19 | Hospices Civils de Lyon | Withdrawn | No outcome recorded |
| Phase 2 | NCT04153032 | Dec 2019 → Jan 2026 overdue | — | American University of Beirut Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03212716 | Dec 2017 → May 2022 | influenza | University Hospital, Lille | Terminated | No outcome recorded |
| Phase 2 | NCT02801305 | Jun 2016 → Jan 2017 | chronic ulcer of skin | Mohammad Ali Nazarinia | Completed | No outcome recorded |
| Phase 2/33 trials · 2 missed | ||||||
| Phase 2/3 | NCT04887818 | Jun → Dec 2021 | ulcer of anus and rectum | University of Calgary | Unknown | No outcome recorded |
| Phase 2/3 | NCT00582777 | Nov 2007 → Dec 2008 | hypertensive nephropathy | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 2/3 | NCT00319982 | Jan 2006 → Dec 2012 | hypertrophic cardiomyopathy | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 38 trials · 1 missed | ||||||
| Phase 3 | NCT06276127 | Apr 2025 → Apr 2027 expected | atrial fibrillation, atrial flutter | Oman Medical Speciality Board | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04372082 | May 2020 → May 2023 | COVID-19 | University Hospital, Lille | Withdrawn | No outcome recorded |
| Phase 3 | NCT04777045 | Oct 2019 → Jul 2026 overdue | coronary microvascular disorder, coronary vasospasm, myocardial ischemia | Radboud University Medical Center | Active not recruiting | Missed primary |
| Phase 3 | NCT01690221 | Oct 2012 → Dec 2013 | ulcer of anus and rectum | Ventrus Biosciences, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01217515 | Oct 2010 → Mar 2012 | ulcer of anus and rectum | S.L.A. Pharma AG | Completed | No outcome recorded |
| Phase 3 | NCT01771978 | Jun 2002 → Feb 2008 | ischemic disease | University Hospital, Strasbourg, France | Unknown | No outcome recorded |
| Phase 3 | NCT00000556 | Mar 1995 → Sep 2002 | atrial fibrillation | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000478 | Nov 1990 → Jun 1997 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 414 trials · 1 met primary | ||||||
| Phase 4 | NCT06534671 | Oct 2024 | Jervell and Lange-Nielsen syndrome | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05294887 | Mar 2022 → Jun 2024 | Prinzmetal angina, coronary microvascular disorder, nonobstructive coronary artery disease | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 4 | NCT04234477 | Dec 2021 → Jun 2022 | atrial fibrillation | Boston University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05261464 | Jan 2021 → Jun 2022 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT04310995 | Jun 2020 → Feb 2023 | coronary artery disorder | Ruijin Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04330300 | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT01162902 | Sep 2013 → Jan 2015 | coronary artery disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01422382 | May → Jun 2011 | — | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01655303 | Feb → Dec 2011 | atrial fibrillation | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00834925 | Aug 2009 | atrial fibrillation | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00893100 | Oct 2007 → Dec 2008 | — | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00712894 | Dec 2006 → Apr 2009 | acute myocardial infarction | Fudan University | Completed | Met primary |
| Phase 4 | NCT00318201 | Apr 2006 → Dec 2007 | — | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT00413712 | Jan 1997 → Mar 2001 | — | Singapore General Hospital | Completed | No outcome recorded |
| Phase not applicable6 trials · 1 met primary | ||||||
| — | NCT05950971 | Jul 2021 → Jan 2022 | paroxysmal atrial fibrillation | Seoul National University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT04513509 | Oct 2020 → Jun 2022 | atrial fibrillation | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT01645826 | Jul 2012 → Sep 2014 | heritable pulmonary arterial hypertension, idiopathic pulmonary arterial hypertension | University of South Florida | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT04222855 | Jan → May 2009 | preeclampsia | Hospital de la Mujer | Completed | Met primary |
| — | NCT00578617 | Sep 2006 → Feb 2009 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00164801 | Nov 2004 → Jan 2007 | — | Chinese University of Hong Kong | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy38 trials | ||||||
| Phase 0 | NCT04017845 Comparator | Apr 2015 → May 2017 | adenomatous colon polyp, colorectal cancer | Lewai Sharki Abdulaziz, MSc PhD | Completed | No outcome recorded |
| Phase 1 | NCT06703463 Background | Oct 2023 → Feb 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04154800 Background | Dec 2019 → Aug 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03070470 Comparator | Mar → Jun 2017 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT02947711 Background | Oct → Nov 2016 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02653872 Comparator | Jan → Apr 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02308748 Comparator | May → Jun 2014 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT01021176 Comparator | Oct → Nov 2009 | — | Pennington Biomedical Research Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT07545187 Comparator | Jun 2025 → Apr 2026 | puerperal infection | Alaa Nadhim Hameed | Completed | No outcome recorded |
| Phase 1/2 | NCT01408524 Comparator | Feb 2010 → Nov 2012 | hypertensive disorder | Mahidol University | Completed | No outcome recorded |
| Phase 1/2 | NCT02503865 Comparator | Jan 2003 → Dec 2008 | metabolic syndrome X | Nazarbayev University | Completed | No outcome recorded |
| Phase 2 | NCT04130438 Comparator | Oct 2020 → Mar 2022 | coronary artery intramyocardial course | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03752931 Comparator | Dec 2018 → Dec 2019 | — | Abderrahmane Mami Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04276298 Comparator | Sep 2020 → Feb 2022 | hemorrhoid | University of Auckland, New Zealand | Completed | No outcome recorded |
| Phase 3 | NCT00803634 Comparator | Dec 2008 → Feb 2012 | heart failure, hypertensive disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 3 | NCT00589303 Comparator | Dec 2007 → Jul 2011 | atrial fibrillation, heart failure | Mayo Clinic | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00313157 Comparator | Apr 2006 → Sep 2010 | atrial fibrillation | Asker & Baerum Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 4 | NCT07103655 Background | Mar → Nov 2026 expected | hypertrophic cardiomyopathy | Second Affiliated Hospital, Zhejiang University, School of Medicine | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06993038 Comparator | Aug 2025 → Jul 2027 expected | cardiac rhythm disease | Anne E. Zepeski | Recruiting | No outcome recorded |
| Phase 4 | NCT07456423 Comparator | Jul 2024 → Jun 2025 | atrioventricular node disorder, cardiac rhythm disease | Haseki Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05122780 Comparator | Jul 2021 → Jul 2025 overdue | myocardial infarction | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05391893 Comparator | Jun 2020 → Apr 2023 | atrial fibrillation, atrial flutter | Corewell Health South | Completed | No outcome recorded |
| Phase 4 | NCT04141553 Comparator | Dec 2019 → Dec 2021 | atrial fibrillation, atrial flutter | Mercy Health Muskegon | Unknown | No outcome recorded |
| Phase 4 | NCT03472495 Comparator | Jun 2018 → Mar 2021 | cardiac rhythm disease | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 4 | NCT03930433 Comparator | Jan 2018 → Mar 2019 | coronary vasospasm | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02695992 Comparator | Feb 2016 → Oct 2021 | atrial fibrillation | Asker & Baerum Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02419534 Comparator | Nov 2014 → Nov 2016 | ulcer of anus and rectum | King Saud University | Unknown | No outcome recorded |
| Phase 4 | NCT02025465 Comparator | Dec 2013 → Feb 2023 | atrial fibrillation, atrial flutter | CAMC Health System | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01914926 Comparator | Jun 2009 → Nov 2010 | cardiac rhythm disease | Antonios Likourezos | Completed | No outcome recorded |
| Phase 4 | NCT00863213 Comparator | Mar 2009 → Mar 2011 | atrial fibrillation | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| — | NCT07445334 Comparator | Mar 2026 → Sep 2027 expected | ventricular tachycardia | Western Sydney Local Health District | Recruiting | No outcome recorded |
| — | NCT06699342 Comparator | Jan 2025 → Dec 2027 expected | atrial fibrillation | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT02364089 Comparator | Apr 2015 → Mar 2022 | adrenal gland disorder | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT02158013 Comparator | Sep 2014 → Feb 2018 | ulcer of anus and rectum | Bispebjerg Hospital | Terminated | No outcome recorded |
| — | NCT02024919 Comparator | Jun 2012 → May 2015 | vascular ectasia | Ankara University | Completed | No outcome recorded |
| — | NCT00911508 Comparator | Nov 2009 → Dec 2017 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-11-01 | Alembic Pharmaceuticals Ltd. | Regulatory Press Release Diltiazem Hydrochloride Tablets alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. |
| 2025-08-11 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg (USRLD: Cardizem® Tablets, 30 mg, 60 mg, 90 mg, and 120 mg). |
| 2024-11-01 | Alembic Pharmaceuticals Ltd. | Regulatory 11th November, 2024, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals announces USFDA Final Approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. |
| 2021-03-23 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity glenmarkpharma.com ↗
Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg |
| 2014-02-12 | Assembly Biosciences | Results Ventrus Biosciences Announces Results From Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure assemblybio.com ↗
The diltiazem 2% treatment arm demonstrated no significant improvement compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation. |
| 2013-09-11 | Assembly Biosciences | Results Ventrus Biosciences Announces Positive Results From Clinical Dermal Safety and Pharmacokinetic Studies of Diltiazem (VEN 307) assemblybio.com ↗
Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced positive results from two clinical dermal safety studies and one pharmacokinetic (PK) study of diltiazem hydrochloride 2% cream (VEN 307). |
| 2012-05-14 | Assembly Biosciences | Results Ventrus Biosciences Announces Positive Results From Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures assemblybio.com ↗
Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported positive results from its Phase 3, randomized, double-blind, placebo-controlled clinical trial of diltiazem hydrochloride cream (VEN 307) in patients with anal fissures. |
| 2011-10-31 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma announces USFDA approval for generic Cardizem CD® sunpharma.com ↗
Sun Pharma announces USFDA approval for generic Cardizem CD® |
All press releases naming this drug 15 releases
Evidence & citations 109 cited values
Every value below carries the sentence it was read from. 106 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | diltiazem | “Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide,...” NCT06699342 ↗102“In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.” NCT00863213 ↗ “IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil.” NCT04234477 ↗ “For example, a dihydropyridine calcium channel blocker (verapamil or diltiazem) may be initiated if patient has concurrent asthma.” NCT07445334 ↗ “additional antihypertensive medication before bedtime [diltiazem 60-120 mg, hydralazine 25 mg, or additional ramipril 5 mg]” PMID 23172931 ↗ Nov 2012 “Within the former group, some were assigned randomly to receive Diltiazem and some to Verapamil.” NCT00413712 ↗ “Amlodipine, diltiazem, felodipine, nicardipine, nifedipine, nimodipine, nitrendipine, verapamil” NCT04330300 ↗ “i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate” NCT05122780 ↗ “Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg” NCT00911508 ↗ “Diltiazem: 30, 60, 120 mg oral capsule may possibly be given” NCT00733239 ↗ “* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg” NCT02364089 ↗ |
| Known as | 2% Diltiazem | “2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)” NCT02080780 ↗ |
| Known as | Adizem | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Adizem-60 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Adizem-sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Adizem-xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Altiazem | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Angiozem 60 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Angiozem cr 120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Angiozem cr 90 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Angitil sr 120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Angitil sr 180 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Angitil sr 90 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Angitil xl 240 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Angitil xl 300 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Anoheal | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Bi-carzem sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Bi-carzem xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Britiazim | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Calazem | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Calcicard | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Calcicard cr | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Cardizem | “Diltiazem (Cardizem), a Moderate CYP3A4 Inhibitor” NCT01124760 ↗ |
| Known as | Cardizem cd | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Cardizem LA | “Diltiazem (Cardizem LA) 240 mg QD” NCT01422382 ↗ |
| Known as | Cardizem sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Cartia | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Cartia xt | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | CRD-401 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Deltazen | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilacor | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilacor xr | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Diladel | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilcardia sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilcardia xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilpral | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilrene | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilt-cd | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | diltiazem (Tiazac) | “diltiazem (Tiazac)” NCT00000620 ↗ |
| Known as | Diltiazem extended release | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Diltiazem hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Diltiazem Hydrochloride | “2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)” NCT02080780 ↗6“Topical Safety Study of Topical Diltiazem Hydrochloride” NCT01816529 ↗ “Diltiazem hydrochloride 4% cream” NCT01217515 ↗ “Diltiazem Hydrochloride 2% Cream” NCT01821274 ↗ “diltiazem hydrochloride 2% cream” NCT01690221 ↗ “Drug: Diltiazem Hydrochloride” NCT01645826 ↗ |
| Known as | Diltiazem hydrochloride in dextrose 5% | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Diltiazem hydrocholoride | “Drug: Diltiazem hydrocholoride” NCT06554639 ↗ |
| Known as | DILTIAZEM MALATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Diltiazem malate component of teczem | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Diltzac | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilzem | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilzem sr 120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilzem sr 60 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilzem sr 90 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilzem xl 120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilzem xl 180 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilzem xl 240 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Dilzene | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Disogram sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Ditiaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Herbessor | “diltiazem (Herbessor)” NCT01408524 ↗ |
| Known as | Horizem sr 120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Horizem sr 60 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Horizem sr 90 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Kentiazem | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Kenzem sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Masdil | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | MK-793 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Monotildiem LP | “receiving 1 capsule per day of diltiazem (Monotildiem® LP) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobectomy for 2 weeks.” NCT03752931 ↗ |
| Known as | NSC-759576 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Optil | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Optil sr 120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Optil sr 180 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Optil sr 90 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Optil xl 240 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Optil xl 300 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Retalzem 60 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | RG 83606 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Slozem | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Slozem 120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Slozem 180 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Slozem 240 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Surazem | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Taztia | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Taztia xt | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Tiamate | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Tiamex | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Tiazac | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Tildiem | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Tildiem la 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Tildiem la 300 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Tildiem ret 120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Tildiem ret 90 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Uard 120xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Uard 180xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Uard 240xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Uard 300xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | VEN307 | “The purpose of this study is to determine if the study drug, VEN307 (diltiazem hydrochloride cream) is safe and to see if it will help with treatment of pain associated with...” NCT01690221 ↗ |
| Known as | Viazem xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Zemret 180 xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Zemret 240 xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Zemret 300 xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Zemtard 120 xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Zemtard 180 xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Zemtard 240 xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Zemtard 300 xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Zilden | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Known as | Zildil sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL23 ↗ |
| Action | Inhibit | “administration of the L-type Ca2+ channel blocker, diltiazem, attenuated the degree of hypertrophic remodeling” NCT00319982 ↗ |
| Modality | Small molecule | — CHEMBL23 ↗ |
| Route | Intravenous | “Both were given as a slow intravenous infusion using a Terumo infusion pump.” NCT00413712 ↗ |
| Target | CYP3A4 | “diltiazem, a well-known CYP3A4 inhibitor” NCT02526888 ↗ |